
usd aug pm et
summari compani primarili provid medic technolog product nich busi
price-to-earnings oper ep
base busi princip serv
stabl global health care sector histori
gener solid revenu profit growth howev
compani financi leverag remain higher
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug stock trade
expect total revenu grow
billion follow growth
support neotract
vascular solut acquisit
confid abil deliv
organ growth increas
invest neotract vascular solut
support momentum see urolift
acquir product neotract key driver
sale growth especi recent posit
data devic urolift shonin approv
japan
follow bp
expans think
continu expand margin
respect
aid improv oper leverag cost
reduct driven restructur effort
benefit restructur effort
initi like off-set partial
new restructur effort
acceler key invest support
urolift sale commerci infrastructur
recent restructur initi
benefit margin
think risk reward
suffici captur current forward price-to-earnings
ratio revenu
 spend weak rel peer
compani prefer make acquisit
nich area boost product portfolio
think took sizabl risk acquir
neotract single-product compani
urolift fortun risk appear
pay may manag note
commerci team train
urologist total us
intend roll-out urolift
aim fulli convert physician base
second-gener devic
risk recommend target
neotract asian market failur
expand margin pricing/reimburs
target base
above-p multipl
ep estim
recent lift valuat multipl
high-end three-year rang due
increas confid compani
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview teleflex incorpor engag develop manufactur suppli
single-us medic devic use hospit health care provid common diagnost
therapeut procedur critic care surgic applic sell product hospit
healthcar provid global combin direct sale forc distributor
product use numer market varieti procedur depend upon one
end market procedur seven report segment vascular north america
emea asia oem segment
tfx vascular north america segment offer product facilit varieti critic care therapi
applic product primarili consist tfx arrow brand cathet relat
devic cathet posit system intervent north america segment consist
product use intervent cardiologist intervent radiologist vascular surgeon vein
practic north america anesthesia north america segment compris compani north
american pain manag airway manag product product like tfx airway
manufactur develop sell comprehens rang surgic product use varieti
europ middl east africa emea asia segment design manufactur distribut medic
devic primarili use critic care surgic applic cardiac care gener serv hospit
health care provid home health specifi region oem segment design manufactur
suppli devic instrument medic devic manufactur tfx busi
includ immateri oper segment respiratory/urolog north america intervent urolog
north america latin america
industri dynam medic devic industri highli competit compet mani
compani rang small start-up enterpris compani larger establish
market character new product develop technolog chang requir compani
continu develop acquir new product technolog remain competit compet
primarili basi clinic superior innov featur enhanc patient benefit product
reliabl perform custom sale support cost effect major end market
hospitals/health care provid revenu medic devic manufactur home
health tfx major competitor includ plc becton dickinson compani boston
vascular solut inc vascular solut neotract medic devic compani
develop commerci urolift system minim invas medic devic treat lower
urinari tract symptom due benign prostat hyperplasia bph vascular solut medic
devic compani develop market clinic product use minim invas coronari
financi trend tfx revenu grew billion bolster recent acquisit
adjust ep compani grew year-over-year reflect five-year compound
annual growth rate compound-annual-growth-rate march compani moder level debt
net debt capit leverag ratio net debt trailing-twelve-month ebitda
free cash flow million million
chairman board
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit new
product launch laxer food drug
administr fda technolog advanc
sub-industri also mani product area
histor recession-resist
equip use non-elect procedur
howev valuat health care equip
compani elev rel
composit suggest posit
fundament reflect share
think higher valuat
sub-industri mostli warrant
strong recent margin expans revenu
growth associ robust product
expect sub-industri earn rise
high-single-digit percentag driven
continu pipelin innov new product
emerg market expans speed
new product come market
increas recent year
success effort fda reduc
approv time medic devic
time see price pressur incess
headwind medic equip compani
impact china-u trade war appear
insignific far medic
equip compani especi sinc
base medic equip manufactur
sourc insignific amount product
input china addit
chines govern seek lower health
care cost provid better health care
insul medic equip
sub-industri mount trade tension
larg medic equip target
chines tariff mean certain
compani
like
hurt trade tension howev bigger
concern medic equip
manufactur potenti trade
tension caus signific slowdown
possibl threat state american
health care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
took control hous repres
period think
see substanti effort
republican trump administr
tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
gener see posit long-term
fundament includ increas global
demand cost-effect value-bas
health care age popul rise
outlay result steadi flow
innov product revenu growth
year-to-d june
vs increas valu
 composit index
vs declin composit
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
incorpor maintain target
above-p ep estim warrant
slight premium peer due recent acquir higher growth busi
ep vs higher estim lower ep
lift ep sale increas
organ million organ revenu growth fell short
expect time order receiv distributor
product constraint associ supplier manag maintain
organ growth guidanc compar organ revenu growth
start acquir neotract busi
expect contribut organ growth headwind expect
revenu repres year-over-year growth /kevin huang cfa
incorpor maintain target
above-p next-twelve-month ep estim reflect
strong sale outlook robust margin expans ep vs
higher estim rais ep
sale increas constant currenc million
includ contribut acquisit neotract vascular
solut organ basi revenu grew expect organ
growth acceler remain quarter
year compani remain driven reduc leverag
debt-ebitda march end
howev dont expect effort prevent make
analyst research note compani news
pm et cfra keep hold opinion share teleflex incorpor
rais target base forward price-to-earnings
multipl ep estim lift
multipl high end rang due increas confid
commerci execut ep vs fell short
estim lift ep sale
increas constant currenc cc million
expect driven impress cc growth america
million cc growth asia million strength asia
led sale growth china howev currenc continu strong
headwind asia neg impact sale slightli less
neg impact intervent urolog busi led
urolift product gener million sale reflect
cc yoy increas growth emea cc expect due
time certain order /kevin huang cfa
pm et cfra keep hold opinion share teleflex incorpor
lift target base above-p
multipl ep estim warrant
premium due recent acquir higher growth busi ep
vs beat consensu expect lift ep
ep sale increas
constant currenc cc million driven
solid cc growth america million cc growth asia
impress currenc neg impact
intervent urolog busi remain strong sale grew cc
million continu uptak urolift devic manag note
commerci team train urologist total
us intend roll-out urolift aim fulli convert
 physician base second-gener devic /kevin huang
pm et cfra reiter hold opinion share teleflex incorpor
maintain target above-p
ep estim warrant premium due
recent acquir higher growth busi ep vs
equal estim lower ep initi
ep sale increas constant currenc
cc million driven cc growth
intervent north america segment million growth
oem segment million intervent urolog sale includ
tfx urolift devic million total sale
continu see urolift key driver sale growth especi
recent posit data devic urolift shonin approv japan
also obtain pre-market approv pma fda manta devic
global market manta approxim million
expect slow limit launch /kevin huang cfa
incorpor lift target
above-p ep estim warrant
premium peer due recent acquir higher growth busi ep
vs higher estim lift ep
sale increas organ million
acquir neotract busi begin contribut organ
growth debut contribut revenu growth octob
neotract urolift system receiv approv market distribut
japan market approxim million men age
moder sever benign prostat hyperplasia bph symptom seen
physician symptom confid abil deliv
organ growth increas invest
neotract vascular solut support strong momentum /kevin huang cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
